To highlight a few discoveries, in AML, the BCL-2 inhibitor Venetoclax synergizes with ribonucleoside analog 8-chloro-adenosine (8-Cl-Ado) to decrease OXPHOS of CD34+CD38− LSC-enriched cells [163]. Here, CD34 is linked to acute myeloid leukemia.